drugset / Trial / NCT04332094
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
RandomizedParallel-groupOpen-labelTreatment
Summary
COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes considerable morbidity and mortality. Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2 infection. This clinical trial is designed to evaluate the use of Tocilizumab in combination with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients with COVID-19.
Timeline
- Start
- 2020-04-02
- Primary completion
- 2021-06
- Completion
- 2021-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | Subcutaneous |
| Background | Azithromycin | Small molecule | 500 mg | Oral |
| Background | Hydroxychloroquine | Small molecule | 200 mg | Oral |